Hims & Hers Health, Inc (NYSE:HIMS) is facing heavy selling pressure Thursday morning as the U.S. Food and Drug Administration's (FDA) ban of compounded drugs with semaglutide takes effect.

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...

Harvard Medical School morgue's former manager, who allegedly stole and sold human remains, pled guilty to interstate ...

The companies are allegedly selling "research grade" GLP-1 weight loss drugs that are not FDA-approved, and are selling the ...

Ozempic, along with its sister drug Wegovy ... issued a medical product alert regarding falsified batches of semaglutide products, specifically Ozempic, detected in Brazil, the UK, and the ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss ...

The restrictions on compounded GLP-1 products come as concerns about existing shortages are bubbling.The FDA declared that shortages of tirzepatide and semaglutide had ended when the drug ...